Chai Discovery vs Cradle (2026)
Both sell protein design as software rather than as a discovery partnership, which already separates them from most of this category, and they differ in what they have chosen to make public. Chai releases named, versioned models with a documented history, quantifies its wet laboratory validation including how many targets were attempted and how many designs were tested, and holds the most complete governance posture in this category, backed by an action rather than a statement. Cradle is the more conventional enterprise product: customers run the platform themselves, there is a published trust centre and security page, and coverage spans pharmaceutical, agricultural, food and chemical protein engineering. For a team that wants a tool their scientists operate across many problems, Cradle. For one whose work is antibody and binder design and who will be asked how the designs were validated, Chai has already answered.
- It is a deployed software product rather than a partnership, with customers running the platform themselves, a trust centre published at a dedicated address and a security page behind it.
- Operational evidence is specific and quantified as of a stated date rather than described in general terms, covering how the platform performs against experimental cycles.
- The applied coverage spans pharmaceutical, biotechnology, agricultural, food and chemical research, so a team can use the same platform across genuinely different protein engineering problems.
- The models are named, versioned and released publicly with a documented history, and the underlying method is described specifically rather than as generative machine learning.
- Wet laboratory validation is quantified with its design stated, including the number of targets attempted and the number of designs tested, which is the disclosure this category most often avoids.
- The most complete governance posture in this category, and the only one backed by a costly action rather than a policy statement, which matters in a field where the designs are novel antibodies and binders.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Chai Discovery and Cradle are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Chai Discovery | Cradle |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2024 | 2022 |
| Headquarters | San Francisco, California | Amsterdam, Netherlands |
| Website | chaidiscovery.com | cradle.bio |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Chai Discovery its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Set against Cradle, Chai Discovery grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Cradle its top capability grade on AI Centrality and Setting and Specialty Coverage. Set against Chai Discovery, Cradle grades higher on several axes, including AI Safety and PHI Stewardship, Security Certifications and Trust Center and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Chai Discovery or Cradle?
On the axes where the AI Health Index separates them, Chai Discovery grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Governance and Bias Disclosure, and Cradle grades higher on several axes, including AI Safety and PHI Stewardship, Security Certifications and Trust Center and Deployment Model and Data Residency. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do Chai Discovery and Cradle differ most?
The widest separation the AI Health Index records between Chai Discovery and Cradle is on Model Supply Chain Disclosure, where Chai Discovery grades A and Cradle grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Chai Discovery and Cradle grade the same?
The AI Health Index grades Chai Discovery and Cradle the same on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
The two operate different deployment models and a buyer's exposure differs accordingly: Cradle sells software the customer runs, while Chai operates two distinct deployment positions whose terms differ, so establish which one you are contracting for before comparing anything else. Neither publishes pricing. Cradle publishes no formal governance framework, model card or bias disclosure, which is the gap against Chai's position. Neither company's designs have been established in humans, so all evidence here is molecular and preclinical and should not be read as clinical validation.